Axovant Sciences Ltd (NASDAQ:AXON) – Equities researchers at Jefferies Group decreased their FY2018 EPS estimates for shares of Axovant Sciences in a research report issued to clients and investors on Monday. Jefferies Group analyst M. Yee now anticipates that the biotechnology company will earn ($2.10) per share for the year, down from their prior estimate of ($1.80). Jefferies Group has a “Hold” rating and a $6.00 price objective on the stock.
A number of other research firms also recently issued reports on AXON. BidaskClub downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a research report on Thursday, October 19th. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 12th. Piper Jaffray Companies reissued a “hold” rating on shares of Axovant Sciences in a research report on Friday, November 10th. Finally, ValuEngine cut shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $13.61.
A number of large investors have recently bought and sold shares of AXON. Oppenheimer & Co. Inc. purchased a new stake in Axovant Sciences during the third quarter valued at approximately $101,000. Cubist Systematic Strategies LLC purchased a new position in shares of Axovant Sciences in the third quarter worth $117,000. Voya Investment Management LLC purchased a new position in shares of Axovant Sciences in the second quarter worth $323,000. Virtus Fund Advisers LLC purchased a new position in shares of Axovant Sciences in the fourth quarter worth $349,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Axovant Sciences by 135.6% in the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock worth $369,000 after buying an additional 30,905 shares during the last quarter. 96.82% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/axovant-sciences-ltd-to-post-fy2018-earnings-of-2-10-per-share-jefferies-group-forecasts-axon.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.